文献速递其他结缔组织病

系统性硬化症相关心肌炎治疗干预前后的心脏磁共振成像

Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本回顾性研究纳入18例系统性硬化症相关症状性心肌炎患者,采用2018修订版Lake Louise标准诊断,在治疗干预后平均8个月复查心脏磁共振。结果显示左心室射血分数提高5.8%、晚期钆增强降低3.1%、T2比值及T2 mapping下降,而T1 mapping和细胞外容积分数无变化。作者认为心脏磁共振可能区分可逆性炎症/纤维化与不可逆纤维化病变,但是否用于监测治疗反应需进一步研究。

要点

  • 治疗后左心室射血分数提高5.8%(s.d. 7.8,P=0.006),右心室射血分数提高4.5%(s.d. 11.4,P=0.085)。
  • 晚期钆增强降低3.1%(s.d. 3.8,P=0.003),6例患者晚期钆增强消退。
  • T2比值降低0.27(s.d. 0.40,P=0.013),T2 mapping降低6.0(s.d. 7,P=0.025),T1 mapping和细胞外容积分数无变化。

核心结论

  • 心脏磁共振可能区分系统性硬化症活动性心肌炎患者的可逆性炎症/纤维化与不可逆纤维化病变,证实系统性硬化症原发性心脏受累的独特性。
  • 心脏磁共振是否及如何用于监测系统性硬化症相关心肌炎的治疗效果需进一步研究。

研究设计与样本

  • 回顾性研究,纳入14例弥漫型及4例局限型系统性硬化症患者(女16/18,年龄56岁(s.d. 11),病程8年(s.d. 11),17/18例有肺部受累),均有心脏症状且超声心动图(4/18)和/或24小时动态心电图(12/14)异常。
  • 心肌炎由心脏磁共振按2018修订版Lake Louise标准诊断。
  • 在给予环磷酰胺(n=11,其中3例联合糖皮质激素、1例联合利妥昔单抗)、霉酚酸酯(n=1)、托珠单抗(n=1)、甲氨蝶呤/糖皮质激素(n=2)、糖皮质激素(n=1)或自体干细胞移植(n=2)后平均8个月(s.d. 3)复查心脏磁共振。

主要发现

  • 与第一次心脏磁共振相比,第二次检查左心室射血分数提高5.8%(s.d. 7.8,P=0.006),右心室射血分数提高4.5%(s.d. 11.4,P=0.085)。
  • 晚期钆增强(目前认为代表替代性纤维化)降低3.1%(s.d. 3.8,P=0.003),6例患者晚期钆增强消退。
  • 心肌水肿标志物T2比值降低0.27(s.d. 0.40,P=0.013),T2 mapping降低6.0(s.d. 7,P=0.025)。
  • T1 mapping(认为反映急性水肿和弥漫性纤维化)和细胞外容积分数(反映弥漫性纤维化)均保持不变。

局限性

  • 心脏磁共振是否及如何用于监测系统性硬化症相关心肌炎的治疗效果需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cardiac magnetic resonance imaging (CMRI) is increasingly used to evaluate cardiac involvement in SSc. We assessed changes, including inflammatory and/or fibrotic myocardial lesions detected by CMRI, following therapeutic interventions for SSc-associated symptomatic myocarditis. METHODS: In this retrospective study, myocarditis was diagnosed by CMRI (2018 revised Lake Louise criteria) in 14 diffuse and 4 limited SSc patients [16/18 women, age 56 years (s.d. 11), disease duration 8 years (s.d. 11), 17/18 with lung involvement] with cardiac symptoms and abnormal findings on echocardiography (4/18) and/or in 24-hour Holter monitoring (12/14). CMRI was repeated after 8 months (s.d. 3) following administration of cyclophosphamide (n = 11, combined with corticosteroids in 3 and rituximab in 1), mycophenolate (n = 1), tocilizumab (n = 1), methotrexate/corticosteroids (n = 2), corticosteroids (n = 1) or autologous stem cell transplantation (n = 2). RESULTS: Functional cardiac improvement was evident by increases in left [by 5.8% (s.d. 7.8), P = 0.006] and right ventricular ejection fraction [by 4.5% (s.d. 11.4), P = 0.085] in the second CMRI compared with the first. Notably, late gadolinium enhancement, currently considered to denote replacement fibrosis, decreased by 3.1% (s.d. 3.8; P = 0.003), resolving in six patients. Markers of myocardial oedema, namely T2 ratio and T2 mapping, decreased by 0.27 (s.d. 0.40; P = 0.013) and 6.0 (s.d. 7; P = 0.025), respectively. Conversely, both T1 mapping, considered to reflect acute oedema and diffuse fibrosis, and extracellular volume fraction, reflecting diffuse fibrosis, remained unchanged. CONCLUSIONS: CMRI may distinguish between reversible inflammatory/fibrotic and irreversible fibrotic lesions in SSc patients with active myocarditis, confirming the unique nature of primary cardiac involvement in SSc. Whether, and how, CMRI should be used to monitor treatment effects in SSc-associated myocarditis warrants further study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Panopoulos S, Mavrogeni S, Vlachopoulos C, et al. Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. Rheumatology (Oxford). 2023. PMID: 36083014. doi:10.1093/rheumatology/keac504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。